Welcome Introduction
·
Hervé de Kergrohen, Chairman, BioData
Official Opening Address
·
Anne Marie
Comparini, President, Rhône-Alpes Region
·
Jacqueline Maurer-Mayor, Minister of Economy, State of
·
Carlo Lamprecht, Minister of
Economy, State of
“A CFO’s view on the biotechnology industry”
·
Allan L. Shaw, Chief
Financial Officer, Serono International
The
top tier biotech companies are generally highly cash generative. Some of them
have also decided to benefit from the current low interest rate environment to
successfully issue convertible bonds. The current situation in the industry
therefore is that there are a relatively small number of large players with
lots of cash and a very much larger number of small players who are rapidly
becoming cash depleted. What are the implications of this dichotomy to the
industry going forward?
“The Genome in 100 Chemical steps”
·
Thane Kreiner, Senior Vice President, Corporate Affairs, Affymetrix
The public domain sequencing of the human and other genomes is opening
new vistas for scientific advancement. For example, genomic information is
revealing previously unknown classes of cancer and possibilities for
dramatically improving patient outcome. Drug development companies have
embraced genomic information to understand mechanisms of action, safety
profiles, and increasingly, to conduct pre-clinical and clinical studies of new
therapeutic candidates. Pharmacogenetics is emerging as an essential
application in the pharmaceutical industry because of its potential to focus
resources on the highest return compounds.
As these applications move towards the clinic, revolutionary tools are
enabling the industrialization of genomics. Since the invention of microarrays
in 1989 by Stephen P.A. Fodor and colleagues, Affymetrix has advanced its
unique technology to package the entire coding portion of the human genome on a
chip the size of a human thumbnail. Innovations such as these hold the promise
of rationalizing the high stakes business of drug development and empowering
new scientific advances that improve human health.
·
Group 1
·
Group 2
“IMS presents its vision of worldwide Pharma/Biotech markets”
·
Carole A. Jones, Consultant
and Practice Area Leader, IMS Global
Consulting
It is estimated that over 10 billion USD in 2000 sales
of biopharmaceuticals will come off patent over the next 5 years in the
In
In the
“What
is the development model of European biotech?”
The gap between European and US Biotech is widening.
The amounts invested are far apart and deal sizes are ten times higher in the
Moderator
·
Juerg Eckhardt, Senior Investment Manager, Global Life
Sciences Ventures
Panellists
·
Jacques Essinger, Chief Executive Officer, IsoTis
·
Sam Fazeli, Senior Biotechnology Analyst, Nomura
·
Antoine Papiernik, Managing Partner,
Sofinnova
·
·
Group 3
·
Group 4
Moderator
·
Cedric Loiret-Bernal, President and
Chief Executive Officer, NanoInk,
Panellists
·
Jerôme Chanton, Fund
Manager,
·
Alexandre
Gauthier-Jaques, Associate Director,
UBS
·
Harry Heinzelmann, Scientific Advisor, NanoDimension
·
Aymeric Sallin, Founder & Managing Partner, NanoDimension
Introduction
·
Robert Kuster, Vice-President, Bioalps
“Swiss Biotech Association: making a
difference?”
·
Domenico Alexakis, Executive
Director, Swiss Biotech Association
The former VSBU/ASBC has revisited the association
strategy early in 2003. Changes in the board of Directors and President have
lead to a more active role of the newly occupied executive office. The name
change of the association is a visible signal to reposition the association
nationally but also internationally. Added value for membership is an important
issue, as well as the creation of a network between the active partners of
science, industry, politics and regulators.
“SARS: What next?”
·
Reinhard Glück, Chief
Scientific Officer, Berna Biotech
On
9:10 – 10:00 Panel
Discussion
“After Amgen, Serono and Genentech, who
are the most attractive biotech and pharma companies that investors should
follow in 2004 and beyond?”
With a market capitalization of USD 80 billion, Amgen
is getting close or even exceeds the market capitalization of some of the
established pharmaceutical companies such as Lilly, Roche or Novartis. The recent
raise of Biotech stocks confirms the attractiveness of this growing industry. Some
predict that the great times of the year 2000 will automatically come back in
the next 2 to 3 years. What will trigger this enthusiasm?
Which
companies have the potential to become world leaders in their markets in 2004
and beyond?
Moderator
·
Hervé de Kergrohen, Chairman, BioData
Panellists
·
Anne-Sophie Borgeaud, VP, Fund
Manager, Life Sciences,
·
Sam Fazeli, Senior Biotechnology
Analyst, Nomura
·
Irene Püttner, Fund Manager
HealthSar, Bank Sarasin
·
Group 5
·
Group 6
·
Group 7
·
Group 8
·
Group 9
·
Group 10
Introduction:
·
Geneviève Morand, Founder and CEO, Rezonance.ch
“Financial: the role of VCs in fostering
innovation? Current trends and drivers”
·
Stéphane Boudon, Chairman, CDC Ixis Innovation
“How should investors and the biopharmaceutical industry assess the
current regulatory environment in the
·
Jean-Yves le Cotonnec, Chief Executive Officer, Triskel
Integrated Services
What impact is the announced change in policy at the
FDA going to have on product approval? What is the position of the European
medicine evaluation agency (EMEA)? Will the industry witness increased
harmonization among the two regulatory agencies? What regulatory processes will
be applied in the future to Biogeneric drugs? To which extents will regulatory
issues and quality control in manufacturing processes impact market
capitalization?”
“Exit
strategies: is the market ready for new IPO’s?”
·
Robert Wyss, Head of Market Development Division and Member of the
Management Committee, SWX Swiss Exchange
Following an intensive period of IPOs around 2000, the
window for public listings has closed. Will the recent increase in valuation
for Biotech stocks, translate into a new round of IPO on the SWX Swiss market?
Which companies are likely to take advantage of such an upturn? What has to be
done in the meantime?
17:20 – 18:00 Panel Discussion
“Biotech incubators in the Rhône-Alpes-Lemanic region: what is new for
start ups?”
Most
governments and other public-funded entities would embrace the concept that
investment in health and medical research is an investment in the future well
being of a nation. Accordingly, a number of initiatives have recently been
announced in the Rhône-Alpes-Lemanic regions, which offer new perspectives for
local start-ups. Though they share the same objective, they are shaped in very
different models (i.e., CNRS tech transfer, Bioincubators and BioPôles).
Moderator
·
Hervé de Kergrohen, Member of the Board, Eclosion
Panellists
·
Jean-Yves Bonnefoy, Managing Director,
Canceropôle Lyon Rhône-Alpes
·
Daniel Christiaen, Business Development
Manager, Rhône-Alpes Genopole
·
Manuel Gea, Vice-President of the biotech committee of the French Pharma
Industry Association, Leem (ex. SNIP)
·
Eric
Halioua, Senior Manager, Arthur
D. Little
·
Nadia Kamal, Deputy Manager, Crealys
·
Robin Offord,
Professor,
Faculty of Science & Medicine, University of
·
Gilles
Talbotier, General Manager, GRAIN
18:00 – 19:00 Networking
cocktail